Navegando por Assunto "Vancomicina"

Agora exibindo 1 - 1 de 1

Linezolida e vancomicina para infecções nosocomiais em pacientes pediátricos: uma revisão sistemática
(Centro Universitário do Estado do Pará, 2023-06-19) Porchera, Bruno Russo; Silva, Carolina Moraes da; Miranda, Rayssa Pinheiro; Brígido, Heliton Patrick Cordovil; http://lattes.cnpq.br/0022669981080887; http://lattes.cnpq.br/1849222504854523; Gomes, Antonio Rafael Quadros; http://lattes.cnpq.br/2884497966458361; Rodrigues, Cybelle Cristina Pereira; http://lattes.cnpq.br/9540610661271303
Objective: This systematic review aimed to investigate the efficacy of linezolid and vancomycin for the treatment of nosocomial infections in children under 18 years old. Method: Five randomized clinical trials, involving a total of 677 children with nosocomial infections and evaluating the efficacy of Linezolid and Vancomycin, were searched in scientific databases: PubMed, Bvs and SciELO. Results: The main nosocomial infections that affected children were bacteremia (BTM), skin and soft tissue infections (CSTI) followed by nosocomial pneumonia (NP). Most infections were caused by Gram-positive bacteria, where all studies showed infections caused by Staphylococcus aureus, with strains of methicillin-resistant S. aureus (MRSA) and methicillin-resistant coagulase-negative Staphylococcus strains being isolated. Both linezolid and vancomycin showed high therapeutic efficacy against different types of nosocomial infections, ranging from 84.4% to 94% for Linezolid and 76.9% to 90% for Vancomycin. Studies have reported that despite adverse events, antimicrobials can be administered for the treatment of nosocomial infections caused by resistant Gram- positive bacteria. Conclusion: Both linezolid and vancomycin have good efficacy in the treatment of resistant Gram-positive bacterial infections in hospitalized children, and linezolid was highlighted in terms of its pharmacological safety.